Introduction/Background*To evaluate the predictive value of pre-treatment haematological parameters including haemoglobin level (Hb), neutrophils lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) on clinical and radiological response for definitive chemoradiation in locally advanced vulvar cancer.

Methodology Charts of patients who were treated at King Hussein Cancer Centre with definitive chemoradiation for pathologically confirmed locally advanced vulvar carcinoma where reviewed. Response to primary disease was labelled as complete response (CR): if no clinical or radiological residual disease at 12 weeks of completion chemoradiation. Univariate analysis for complete response, progression free survival (PFS) and overall survival (OS) were performed using clinical factors and pre-treatment hematological parameters.

Result(s)*Out of 30 patient who were included in analysis, with mean follow up of 27 months, range (6.7-78); 24 patients achieved CR (80%) at 12 weeks of treatment completion. On follow up (mean 27 months), 12 patient developed disease progression (40%) and 9 patients died (30%). Low pre-treatment NLR (<3.8) was significant prognostic factor for achieving CR (p<0.049), higher PFS (p<0.0067) and OS (p<0.0001). Low pre-treatment PLR showed higher PFS (p<0.0276), while pretreatment Hb was not associated with prognosis.

• Download figure
• Open in new tab
• Download powerpoint

Abstract 490 Figure 1

Conclusion*Pre-treatment NLR may be useful as predictive tool to predict clinical and radiological response and oncological outcomes for locally advanced vulvar cancer treated with definitive chemoradiation.